Business
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities
PLYMOUTH MEETING, Pa., May 07, 2026--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today reported Q1 2026 revenue of $215.4 million, delivering 17% year‑over‑year growth for WAKIX®. Performance during the quarter reflected continued strong demand, offset by market access headwinds observed every Q1, which were more pronounced this year. This follows the strongest three consecutive quarters in franchise history, and the Company reinforced 2026 full year revenue guidance. The Company also outl
About this update from Harmony Biosciences Holdings, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":4113,"height":1051,"url":"https://media.zenfs.com/en/business-wire.com/46ec6a09322e79805da96befec6c72aa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FhnmhsnO3XgyllzjbuleTg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI0NQ--/https://media.zenfs.com/en/business-wire.com/46ec6a09322e79805da96befec6c72aa","width":960,"height":245},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/G5gWSTOQIZ.HG12_MWCcfg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTE2NA--/https://media.zenfs.com/en/business-wire.com/46ec6a09322e79805da96befec6c72aa","width":640,"height":164},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/8yv3Nh36EgWrrOa0rJ.lxw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02MTQ-/https://media.zenfs.com/en/business-wire.com/46ec6a09322e79805da96befec6c72aa","width":1200,"height":307}},"lazy":false},{"type":"text","content":"WAKIX® Net Revenue Grew 17% to $215.4 Million for First Quarter 2026; On Track for Full Year 2026 Net Revenues over $1 Billion","length":126,"tagName":"p","attribs":{}},{"type":"text","content":"Continue to Vigorously Protect WAKIX IP into 2030; Filed Suit Against AET Pharma/Sandoz Regarding Infringement of Amorphous Pitolisant Patent","length":141,"tagName":"p","attribs":{}},{"type":"text","content":"Lifecycle Management Advancing with Pitolisant GR on Track for NDA Filing 2Q26, Pitolisant HD Phase 3 Data in 2027, and Recently Acquired Novel Amorphous Form of Pitolisant to Pursue Broader CNS Indications","length":206,"tagName":"p","attribs":{}},{"type":"text","content":"Potential Best-in-Class Orexin-2 Agonist with BP-205; Phase 1 Clinical PK Data On Track for Mid-2026","length":100,"tagName":"p","attribs":{}},{"type":"text","content":"Renewed Focus on Business Development Opportunities with Emphasis on Revenue Potential in the 2028 to 2032 Timeframe","length":116,"tagName":"p","attribs":{}},{"type":"text","content":"Expansion of the Leadership Team with the Addition of New COO and CFO to Support Scale and Next Phase of Growth","length":111,"tagName":"p","attribs":{}},{"type":"text","content":"Conference Call and Webcast Today at 8:30 a.m. ET","length":49,"tagName":"p","attribs":{}},{"type":"text","content":"PLYMOUTH MEETING, Pa., May 07, 2026--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. ...